SaxaDapa
Author: Kevin Shannon
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
SaxaDapa is a fixed-dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT-2) inhibitor Farxiga (dapagliflozin; AstraZeneca) and dipeptidyl peptidase-IV inhibitor Onglyza (dapagliflozin; AstraZeneca/Kyowa Hakko Kirin).
SaxaDapa is the second FDC containing an SGLT-2 inhibitor and a DPP-IV inhibitor approved to treat type 2 diabetes in the US and EU.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 SaxaDapa : Diabetes type 2
LIST OF FIGURES
9 Figure 1: SaxaDapa for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare drug assessment of SaxaDapa
11 Figure 3: Datamonitor Healthcare drug assessment scorecard for SaxaDapa compared to Januvia
LIST OF TABLES
4 Table 1: SaxaDapa drug profile
6 Table 2: SaxaDapa Phase III data in type 2 diabetes
9 Table 3: SaxaDapa Phase III trials in type 2 diabetes
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Toujeo 
Sign up to the